Biocryst Pharmaceuticals (BCRX) Other financing activities (2010 - 2026)

Biocryst Pharmaceuticals' Other financing activities history runs 17 years deep, the most recent figure standing at $19.5 million for Q1 2026.

• Quarterly Other financing activities rose 715.02% year-over-year to $19.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $26.2 million (up 530.97% YoY) and the FY2025 annual result came in at $9.1 million, up 164.66% from the prior year.
• Other financing activities was $19.5 million for Q1 2026 at Biocryst Pharmaceuticals, up from $657000.0 in the prior quarter.
• Across five years, Other financing activities topped out at $19.5 million in Q1 2026 and bottomed at -$586000.0 in Q4 2024.
• A 5-year average of $3.2 million and a median of $2.1 million in 2024 frame the typical range for Other financing activities.
• Annual changes were most pronounced in 2024 — Other financing activities tumbled 1602.56% — and 2025, when it jumped 1195.83%.
• Biocryst Pharmaceuticals' Other financing activities stood at $4.0 million in 2022, then tumbled by 99.03% to $39000.0 in 2023, then tumbled by 1602.56% to -$586000.0 in 2024, then soared by 212.12% to $657000.0 in 2025, then surged by 2864.84% to $19.5 million in 2026.
• Business Quant data shows BCRX's Other financing activities at $19.5 million in Q1 2026, $657000.0 in Q4 2025, and $2.6 million in Q3 2025.